O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
-3.5%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$4.82B
AUM Growth
+$4.82B
(-12%)
Cap. Flow
-$176M
Cap. Flow
% of AUM
-3.65%
Top 10 Holdings %
Top 10 Hldgs %
44.7%
Holding
132
New
19
Increased
23
Reduced
22
Closed
17
Top Buys
| 1 |
UPB
Upstream Bio, Inc. Common Stock
UPB
|
$93.6M |
| 2 |
Neurocrine Biosciences
NBIX
|
$86.8M |
| 3 |
Edwards Lifesciences
EW
|
$84.8M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
$38.9M |
| 5 |
Cytokinetics
CYTK
|
$38.4M |
Top Sells
| 1 |
Amgen
AMGN
|
$81.3M |
| 2 |
Elevance Health
ELV
|
$55.2M |
| 3 |
Merck
MRK
|
$48.4M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
$47.5M |
| 5 |
Evolent Health
EVH
|
$47.1M |
Sector Composition
| 1 | Healthcare | 98.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
Cassava Sciences
SAVA
$110M
| – | – | 0 | – | – |
|
127
Syndax Pharmaceuticals
SNDX
$1.41B
| – | – | -1,925,300 | Closed | -$37.1M |
|
128
TELA Bio
TELA
$70.5M
| – | – | -2,161,185 | Closed | -$5.47M |
|
|
VIGL
129
DELISTED
Vigil Neuroscience
VIGL
| – | – | -448,891 | Closed | -$1.53M |
|
130
Solventum
SOLV
$12.7B
| – | – | 0 | – | – |
|
|
LBPH
131
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| – | – | -170,000 | Closed | -$5.67M |
|